CSI Market
Sign In | Register

Cerevel Therapeutics Holdings Inc (CERE) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access CERE quarterly Cash Flow →
Cash flow data covering Cerevel Therapeutics Holdings Inc–Aug 31 2015 offers a view into how Dec 31 2023's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2023)
12 Months 		(Dec 31 2022) (Dec 31 2021) (Dec 31 2020) (Aug 31 2015)
Operating Activities
Income-432.84
Depreciation & amortization5.63
Amortization of Other Assets1.94
Increase (Decrease) in Deferred Revenue0.00
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation69.41
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Adjustment For Modification Of Liability Classified Warrants-
Interest Income Operating-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable2.04
Increase (Decrease) in Accrued Liabilities17.41
Increase (Decrease) in Billing in Excess of Cost of Earnings0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.99
Other Working Capital-1.34
Other Noncash Income (Expense)-0.01
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.35
Discontinued operations0.00
Net Cash flow from Operating Activities-342.30
Investing Activities
Capital Expenditures-3.81
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities942.80
Payments to Acquire Marketable Securities-865.27
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash and Investments0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Insurance Settlement, Investing Activities0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities73.72
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.14
Long-term debt - borrowings15.63
Long-term debt - repayments15.63
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock517.51
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-138.39
Proceeds From Issuance Of Debt And Preferred Stock Warrants-
Proceeds From Issuance Of Preferred Stock And Common Stock Warrants138.39
Stock Issuance Cost-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities548.62
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-346.11
Total Cash Flow280.04
4 historic quarters locked

Sign in to unlock the full Cerevel Therapeutics Holdings Inc cash flow history.

Sign In Create Free Account

About Cerevel Therapeutics Holdings Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20231231)
  • Filed with the SEC: February 27, 2024
  • Source: cere-20231231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-24-021078

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License